MyFinsight
Home
Blog
About
Sale of common stock
for cash
$584K
(-97.88%↓ Y/Y)
Exercise of warrants for
cash
$130K
(12900.00%↑ Y/Y)
Exercise of stock options
for cash
$35K
Net cash provided by
financing activities
$749K
(-97.28%↓ Y/Y)
Net (decrease)
increase in cash and cash...
-$2,947K
(-123.67%↓ Y/Y)
Canceled cashflow
$749K
Stock-based compensation
$1,358K
(-62.38%↓ Y/Y)
Accounts payable and
accrued liabilities
$394K
(-65.19%↓ Y/Y)
Other assets
-$146K
(-129.74%↓ Y/Y)
Prepaid expenses
-$73K
(-141.95%↓ Y/Y)
Depreciation expense
$66K
Operating lease
liabilities
$58K
Net cash used in
operating activities
-$3,175K
(77.64%↑ Y/Y)
Canceled cashflow
$2,095K
Net cash used in
investing activities
-$430K
(39.09%↑ Y/Y)
Impact on cash from
foreign currency...
-$91K
(51.60%↑ Y/Y)
Research and development
tax credit...
$3,934K
(827.83%↑ Y/Y)
Net loss
-$1,273K
(96.28%↑ Y/Y)
Other tax receivable
$63K
(-80.43%↓ Y/Y)
Purchase of equipment
$430K
(-39.09%↓ Y/Y)
Back
Back
Cash Flow
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)
source: myfinsight.com